1929.3000 -33.30 (-1.70%)
NSE Oct 08, 2025 15:31 PM
Volume: 306.7K
 

1929.30
-1.70%
BP Wealth
Glenmark Pharma (GPL) earnings came above our estimate. The company posted revenues of Rs 23.6bn with 20% YoY growth which was above our estimate of Rs 22.8bn. EBITDA margin, at 25.1%, was above our estimate of 22.1% due to favorable product mix . Adj.PAT increased at much higher...
Glenmark Pharmaceuticals Ltd. is trading below its 30 day SMA of 2014.8
More from Glenmark Pharmaceuticals Ltd.
Recommended